Developing targeted cancer therapeutics that delivers a potent, unique & patented drug that directly treats breast, prostate, bladder, kidney, and lung cancer.


Our innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects with the best way to cure or extend human life.

According to the International Agency for Research on Cancer (IARC), in 2018 there were an estimated 17.0 million new cancer cases and 9.6 million cancer deaths worldwide.

In 2019 in the U.S., there will be an estimated 1,762,450 new cancer cases and 606,880 cancer deaths.

That’s approximately 4,830 new cases and 1,660 deaths every day.

Cancer is the second leading cause of death globally, and is responsible for an estimated
9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.

These are the common cancer killers we’re working to treat and cure.

Breast Cancer

2,090,000 Cases
627,000 Deaths

Prostate Cancer

1,276,000 Cases
359,000 Deaths

Bladder Cancer

549,000 Cases
199,900 Deaths

Kidney Cancer

403,000 Cases
175,000 Deaths

Our technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company’s drug candidates within a tumor. Inspyr’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors.

Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.